Table 2.
Baseline clinicopathologic characteristics of patients with second-line treatment
| Clinicopathologic characteristic | Cetuximab group | Chemotherapy alone group | P valuec | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| All patients | RSCC | LSCRC | P value | All patients | RSCC | LSCRC | P value | ||||
| No. of patients | 96 | 28 | 68 | — | 93 | 44 | 49 | — | 0.011* | ||
| Median age at diagnosis | |||||||||||
| ≤65 years | 82 (85.4) | 21 (75.0) | 61 (89.7) | 0.108 | 72 (77.4) | 30 (68.2) | 42 (85.7) | 0.051 | 0.191 | ||
| >65 years | 14 (14.6) | 7 (25.0) | 7 (10.3) | 21 (22.6) | 14 (31.8) | 7 (14.3) | |||||
| Sex | 0.488 | 1.000 | 0.105 | ||||||||
| Male | 63 (65.6) | 20 (71.4) | 43 (63.2) | 50 (53.8) | 24 (54.5) | 26 (53.1) | |||||
| Female | 33 (34.4) | 8 (28.6) | 25 (36.8) | 43 (46.2) | 20 (45.5) | 23 (46.9) | |||||
| ECOG performance status | 0.074 | 0.438 | 0.310 | ||||||||
| 0 | 53 (55.2) | 13 (46.4) | 40 (58.8) | 41 (44.0) | 19 (43.2) | 22 (44.9) | |||||
| 1 | 35 (36.5) | 11 (39.3) | 24 (35.3) | 42 (45.2) | 22 (50.0) | 20 (40.8) | |||||
| ≥2 | 8 (8.3) | 4 (14.3) | 4 (5.9) | 10 (10.8) | 3 (6.8) | 7 (14.3) | |||||
| Pathology | 0.102 | 0.183 | 0.822 | ||||||||
| Adenocarcinoma | 84 (87.5) | 22 (78.6) | 62 (91.2) | 83 (89.2) | 37 (84.1) | 46 (93.9) | |||||
| Mucinous & signet-ring cell | 12 (12.5) | 6 (21.4) | 6 (8.8) | 10 (10.8) | 7 (15.9) | 3 (6.1) | |||||
| Metastasis | 0.804 | 1.000 | 0.005* | ||||||||
| Single | 69 (71.9) | 21 (75.0) | 48 (70.6) | 48 (51.6) | 23 (52.3) | 25 (51.0) | |||||
| Multiple | 27 (28.1) | 7 (25.0) | 20 (29.4) | 45 (48.4) | 21 (47.7) | 24 (49.0) | |||||
| Metastasis resection | 24 (25.0) | 6 (21.4) | 18 (26.5) | 0.796 | 16 (17.2) | 11 (25.0) | 15 (30.6) | 0.646 | 0.215 | ||
| Total cycles of cetuximab (median) | 5 (2-20) | 4 (2-13) | 5 (2-20) | 0.272 | — | — | — | — | — | ||
| Total cycles of chemotherapy (median) | 8 (2-66) | 7 (4-35) | 8 (2-66) | 0.548 | 6 (2-36) | 6 (2-36) | 6 (2-27) | 1.000 | 0.031* | ||
| All three active drugsa | 87 (90.6) | 24 (85.7) | 63 (92.6) | 0.441 | 84 (90.3) | 39 (88.6) | 45 (91.8) | 0.731 | 1.000 | ||
| Backbone chemotherapy | 0.139 | 1.000 | 0.745 | ||||||||
| Oxaliplatin-based | 27 (28.1) | 11 (39.3) | 16 (23.5) | 24 (25.8) | 11 (25.0) | 13 (26.5) | |||||
| Irinotecan-based | 69 (71.9) | 17 (60.7) | 52 (76.5) | 69 (74.2) | 33 (75.0) | 36 (73.5) | |||||
| Bevacizumab during the disease | 27 (28.1) | 11 (39.3) | 16 (23.5) | 0.637 | 22 (23.7) | 8 (18.2) | 14 (28.6) | 0.329 | 0.510 | ||
| Recurrent diseaseb | 42 (43.8) | 6 (21.4) | 36 (52.9) | 0.006* | 33 (35.5) | 19 (43.2) | 14 (28.6) | 0.199 | 0.298 | ||
All values are presented as the number of patients followed by percentages in parentheses. a Patients who received 5-fluorouracil, oxaliplatin, and irinotecan during the course of their disease. b Patients who had metastatic disease after curative-intent primary tumor resection. c Patient characteristics were compared between the cetuximab and chemotherapy groups. Other footnotes as in Table 1